Home-based telerehabilitation for rural men with advanced prostate cancer
Official title: Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
Run by University of Utah · NCT07093177 · Data updated 2026-11-12
This 12-week home telerehabilitation program will try guided exercise and rehabilitation for men in rural areas who are on androgen-deprivation therapy for high-risk or metastatic prostate cancer to see if it's usable, acceptable, and helps them stick with exercise.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | University of Utah Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Salt Lake City, Utah) |
| Status | Recruiting |
| Started | February 24, 2026 |
| Main results expected | September 2028 |
| Study ends | September 2028 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT07093177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18 or older with confirmed prostate cancer who are receiving standard ADT for high‑risk, locally advanced, or metastatic disease and who live in a rural RUCA zip code, without unstable cardiac or painful/unstable bony metastases, are ideal candidates.
✕Probably not a fit
Patients with unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bone metastases, recent fractures, those already in a regular exercise rehabilitation program, or those unable to use telehealth are unlikely to receive benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Men receiving androgen-deprivation therapy for high‑risk or metastatic prostate cancer who live in rural areas will participate in a 12‑week multimodal telerehabilitation program delivered via a telerehabilitation unit. The intervention combines remotely supervised exercise, functional rehabilitation, and patient education delivered through telemedicine. The pilot will measure usability, acceptability, and exercise adherence over the 12 weeks and record barriers and facilitators to participation. Results will inform feasibility and design of larger trials to improve access to cancer rehabilitation in rural communities.
Why it matters
Potential benefit: If successful, the program could expand access to rehabilitation for rural patients, improve physical function and quality of life, and increase adherence to exercise during ADT.
How similar studies have gone: Previous pilot work showed high acceptance of home telerehabilitation in older adults and positive feasibility signals in advanced bladder cancer, but systematic testing in rural advanced prostate cancer is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and older * Confirmed diagnosis of prostate cancer * Men receiving standard-of-care ADT either for high-risk, locally advanced prostate cancer or as a part of multicomponent management of metastatic prostate cancer * Residing in a rural community, as indicated by zip code in RUCA areas Exclusion Criteria: * Unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures * Engaged in a regular exercise rehabilitation program * Relocation plans within next 3 months * Participating in another clinical trial * Have a working telephone line in their home or a cell phone.
Where it's running
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, United States Recruiting
Study contacts
- Principal investigator: Manish Kohli, MD — Huntsman Cancer Institute
- Study coordinator: Manish Kohli, MD
- Email: Manish.Kohli@hci.utah.edu
- Phone: 801-646-4018
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.